Frontdoor, Inc. (NASDAQ:FTDR – Get Free Report) shot up 6.8% during mid-day trading on Monday . The company traded as high as $53.03 and last traded at $52.91. 593,845 shares were traded during trading, a decline of 18% from the average session volume of 721,167 shares. The stock had previously closed at $49.52.
Analyst Upgrades and Downgrades
FTDR has been the topic of a number of recent research reports. JPMorgan Chase & Co. upped their target price on shares of Frontdoor from $45.00 to $55.00 and gave the company an “overweight” rating in a report on Monday, August 12th. Truist Financial boosted their price target on Frontdoor from $45.00 to $56.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. The Goldman Sachs Group raised their target price on Frontdoor from $33.00 to $41.00 and gave the company a “sell” rating in a research note on Friday, August 2nd. Finally, William Blair upgraded shares of Frontdoor from a “market perform” rating to an “outperform” rating in a research note on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, Frontdoor has a consensus rating of “Hold” and a consensus target price of $47.75.
Check Out Our Latest Stock Analysis on Frontdoor
Frontdoor Price Performance
Frontdoor (NASDAQ:FTDR – Get Free Report) last announced its earnings results on Thursday, August 1st. The company reported $1.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.27. The firm had revenue of $542.00 million during the quarter, compared to analyst estimates of $536.74 million. Frontdoor had a return on equity of 132.94% and a net margin of 11.38%. The business’s revenue was up 3.6% compared to the same quarter last year. During the same period last year, the firm posted $0.87 EPS. As a group, analysts anticipate that Frontdoor, Inc. will post 2.79 earnings per share for the current year.
Institutional Investors Weigh In On Frontdoor
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Exchange Traded Concepts LLC bought a new stake in shares of Frontdoor in the third quarter worth approximately $27,000. V Square Quantitative Management LLC purchased a new position in Frontdoor during the third quarter valued at approximately $31,000. GAMMA Investing LLC increased its stake in Frontdoor by 90.7% in the 2nd quarter. GAMMA Investing LLC now owns 879 shares of the company’s stock worth $30,000 after buying an additional 418 shares in the last quarter. Quarry LP raised its stake in Frontdoor by 468.1% during the 2nd quarter. Quarry LP now owns 1,085 shares of the company’s stock valued at $37,000 after purchasing an additional 894 shares during the period. Finally, Covestor Ltd lifted its holdings in shares of Frontdoor by 288.6% in the first quarter. Covestor Ltd now owns 1,154 shares of the company’s stock worth $38,000 after buying an additional 857 shares in the last quarter.
Frontdoor Company Profile
Frontdoor, Inc provides home warranties in the United States in the United States. Its customizable home warranties help customers protect and maintain their homes from costly and unplanned breakdowns of essential home systems and appliances. The company’s home warranty customers subscribe to an annual service plan agreement that covers the repair or replacement of principal components of approximately 20 home systems and appliances, including electrical, plumbing, water heaters, refrigerators, dishwashers, and ranges/ovens/cooktops, as well as electronics, pools, and spas and pumps; and heating, ventilation, and air conditioning systems.
See Also
- Five stocks we like better than Frontdoor
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Intel: Is Now the Time to Be Brave?Â
- 3 Fintech Stocks With Good 2021 Prospects
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- The Risks of Owning Bonds
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Frontdoor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Frontdoor and related companies with MarketBeat.com's FREE daily email newsletter.